



www.genfit.com

GENFIT SUCCESSFULLY RAISES MORE THAN 14M€ INCREASING ITS CASH POSITION TO 30M€

This document shall not be published, distributed or disclosed, either directly or indirectly in the United States of America, in Canada, in Japan or in Australia. This press release is for information purposes only and does not constitute an offering document.

Lille (France), April 15th, 2013 – GENFIT (Alternext: ALGFT; ISIN: FR0004163111), a biopharmaceutical company at the forefront of drug discovery and development, focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, today announces that it has raised 14,325,000.72€ in the frame of a capital increase of an nominal amount of 732.362,00 € through a private placement of new shares to French and Foreign qualified investors via an accelerated bookbuilding procedure.

This private placement which was announced on Friday 12 April 2013 after closing of the market has allowed GENFIT to issue 2,929,448 new shares, at a price of 4.89€ per share, representing a 19.7% discount based on the volume-weighted average price of 5 trading days during the period between 25 March and 2 April 2013 (which is equivalent to a discount of 20% on the average price of the last 20 closing prices). This operation is within the limits stipulated by the 17th resolution of the company's Combined Shareholders' Meeting held on the 26th of June 2012, which approved the issuance of up to 2,933,800 shares and not to exceed a maximum of 20% of the capital. This issue represents 14.43% of the outstanding number of shares and will bring the total number of shares after the issue to 20,299,516. Following their issuance, the new shares will be admitted to trading on NYSE Alternext Euronext which is expected to take place on 22 April 2013.

An additional capital increase of 2 to 5 million euros (share premium included) with preferential subscription rights will be proposed for a vote by a forthcoming combined Shareholders' Meeting to be convened. Similar discount terms will be proposed.

The funds raised will be used by GENFIT to:

- Pursue the development of its most advanced drug candidate, GFT505, in phase IIb, in order to maximize its value in preparation of out-licencing the commercial rights before the start of phase III,
- Allow the rapid advancement of other programs in its pipeline, namely the development of compounds in preclinical phase, discovered in the programs TGFTX1 and TGFTX3 for partnership alliances.

Portzamparc Société de Bourse was the sole lead manager and sole bookrunner of the present operation. Bionest Partners Finance advises GENFIT in its financial investment strategy.

Jean-François Mouney, Chairman and Chief Executive Officer of GENFIT, commented: *We are fully satisfied with the success of this private placement which largely recognizes the very positive results obtained by GENFIT in its different programs.*

These new resources, which bring the cash position of GENFIT to 30M€, will allow us to develop further the products in our pipeline, with first and foremost GFT505.

We thank the different qualified investors who invested in this private placement, and particularly some of our historical shareholders who wished to participate; we are happy to welcome an international investor of reference, the very major participant in this capital increase, who thus marks its large interest in the development of GENFIT. This investor is a large "family office" specialized inter alia in the Life Sciences sector.

On another note, we foresee to ask our next Combined Shareholders' Meeting to authorize an additional capital increase, with preferential subscription rights and at similar discount terms, which will particularly benefit numerous individual investors who show confidence in our company.

About GENFIT:

GENFIT is a biopharmaceutical company focused on the Discovery and Development of drug candidates in therapeutic fields linked to cardiometabolic disorders (prediabetes/diabetes, atherosclerosis, dyslipidemia, inflammatory diseases...). GENFIT uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments and advances therapeutic research programs, either independently or in partnership with leading pharmaceutical companies, including Sanofi, to address these major public health concerns and their unmet medical needs.

GENFIT's research programs have resulted in the creation of a rich and diversified pipeline of drug candidates at different stages of development, including GENFIT's lead proprietary compound, GFT505, that is currently in Phase IIb.

With facilities in Lille, France, and Cambridge, MA (USA), the Company has approximately 80 employees. GENFIT is a public company listed on the Alternext trading market by Euronext™ Paris (Alternext: ALGFT; ISIN: FR0004163111). www.genfit.com

Contacts:

GENFIT

Jean-François Mouney – CEO & Chairman of the Management Board
Ph. +333 2016 4000

MILESTONES – Press Relations

Bruno Arabian Ph. +33 1 7544 8740 / +336 8788 4726 – barabian@milestones.fr

Warnings

This issuing of Genfit shares, described in the present announcement, has been made exclusively in the course of a private placement to qualified investors in accordance with article L. 411-2 of the French Monetary and Financial Code and applicable regulations. It does not constitute an offer to the public within the meaning of L. 411-1 of the Monetary and Financial Code and does not result in a prospectus filed with the Autorité des marchés financiers.

This press release does not constitute and shall not be interpreted as constituting a public offer or a subscription offer or as soliciting the interest of the public with a view to making a public offer in any jurisdiction whatsoever.

This press release does not constitute either a prospectus within the meaning of directive 2003/71/EC of the European parliament and council of November 4, 2003 (as implemented in each of the member of the European Economic Area). No action has been taken or will be taken to permit a public offer of Genfit shares that would require the publication of a prospectus in any member state or any filing or registration with any regulatory authority in any State whatsoever.

This press release does not constitute and is not part of an offer or any solicitation of an offer to purchase or subscribe for securities in the United States of America or in any State of United State of America. Genfit's shares may not be offered or sold in the United States of America except in case of registration or under an exemption for registration under the US securities act of 1933, as amended. Genfit has no intention to register

the shares issued in this placement, subject matter of this press release, or part thereof in the United States of America or of making any public offering for its securities in the United States of America. This press release may not be published, distributed or transferred, directly or indirectly, in the United States of America.

The distribution of this document may, in several countries, be subject to specific regulations. Persons into whose possession this document comes should inform themselves about potential local restrictions and comply with them